Indian Journal of Public Health Research & Development

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Oral Plasmablastic Lymphoma in an HIV Negative Patient - a Case Report


Affiliations
1 Dept. of Medical Oncology, KMIO, India
2 Dept. of Medical Oncology, Kidwai Memorial Institute of Oncology, (KMIO), Bangalore -29, India
     

   Subscribe/Renew Journal


Plasmablastic lymphoma (PBL) is a rare variant of a diffuse B-cell lymphoma that is most commonly found in the oral cavity affecting the mucosa, and so named for its blastoid morphology and immunophenotype. Oral PBL has been treated heterogeneously and well defined treatment guidelines are still lacking. It includes chemotherapy, radiotherapy, combination of both or local excision followed by radiation. Prognosis is usually poor regardless of the site of origin. The clinical course is very aggressive with most of the patients dying in the first year after diagnosis. Here we present a case who was treated with high grade lymphoma protocol, CODOX-M alternating with IVAC followed by radiotherapy&Patient showing a good clinical response.

Keywords

Oral Plasmablastic Lymphoma, HIV-Negative, CODOX-M (Cyclophosphamide O-vinccristine DOX-doxorubicin M-methotrexate), IVAC (I-ifosfamide V-vincristine A-cytosine arabinoside C-cisplatin), LCA(Leucocyte Common Antigen)
Subscription Login to verify subscription
User
Notifications
Font Size



  • Oral Plasmablastic Lymphoma in an HIV Negative Patient - a Case Report

Abstract Views: 367  |  PDF Views: 0

Authors

Punit Chitlangia
Dept. of Medical Oncology, KMIO, India
Samit Purohit
Dept. of Medical Oncology, KMIO, India
Chintan Narad
Dept. of Medical Oncology, Kidwai Memorial Institute of Oncology, (KMIO), Bangalore -29, India
Rohan Bhise
Dept. of Medical Oncology, Kidwai Memorial Institute of Oncology, (KMIO), Bangalore -29, India

Abstract


Plasmablastic lymphoma (PBL) is a rare variant of a diffuse B-cell lymphoma that is most commonly found in the oral cavity affecting the mucosa, and so named for its blastoid morphology and immunophenotype. Oral PBL has been treated heterogeneously and well defined treatment guidelines are still lacking. It includes chemotherapy, radiotherapy, combination of both or local excision followed by radiation. Prognosis is usually poor regardless of the site of origin. The clinical course is very aggressive with most of the patients dying in the first year after diagnosis. Here we present a case who was treated with high grade lymphoma protocol, CODOX-M alternating with IVAC followed by radiotherapy&Patient showing a good clinical response.

Keywords


Oral Plasmablastic Lymphoma, HIV-Negative, CODOX-M (Cyclophosphamide O-vinccristine DOX-doxorubicin M-methotrexate), IVAC (I-ifosfamide V-vincristine A-cytosine arabinoside C-cisplatin), LCA(Leucocyte Common Antigen)

References